Humanized PcrV Antibody Neutralizing Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Pseudomonas aeruginosa infections are hindered by the bacteria's low sensitivity to antibiotics and rapid antibiotic resistance, necessitating a non-antibiotic therapeutic approach, with existing monoclonal antibodies exhibiting low neutralizing activity against PcrV, a key virulence factor.
Innovation Solution
Development of a humanized monoclonal antibody specifically targeting PcrV, with enhanced neutralizing activity, characterized by specific amino acid sequences and epitope recognition, capable of inhibiting cytotoxicity at low concentrations and exhibiting high affinity, thereby effectively treating Pseudomonas aeruginosa infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies against PcrV are used, then they can provide a non-antibiotic therapeutic approach, but they exhibit low neutralizing activity and fail to satisfy clinical requirements
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the monoclonal antibody to achieve higher neutralizing activity. Specifically, the antibody has been engineered with optimized complementarity determining regions (CDRs) that bind to PcrV with higher affinity, resulting in IC50 values below 100 nM compared to the low activity of conventional antibodies. This parameter optimization resolves the contradiction between reliability and therapeutic effectiveness.
2Ease of manufacture
If polyclonal antibodies are used against PcrV, then they can be produced, but they are difficult to be humanized and used as pharmaceutical compositions due to antigenicity issues
Solution Approach 1:
The patent inverts the conventional approach by starting with a humanized monoclonal antibody framework and then optimizing it for anti-PcrV activity, rather than attempting to humanize polyclonal antibodies. This inversion allows the antibody to maintain low antigenicity in humans while achieving high neutralizing activity through rational design of the CDR regions, thereby resolving the contradiction between ease of manufacture and adaptability for human use.
3Reliability
Pseudomonas aeruginosa has low sensitivity to antibiotics and high tendency to acquire resistance, but new antibiotic development is limited
Solution Approach 1:
The patent introduces an intermediary approach by using a monoclonal antibody that targets PcrV, a virulence factor, rather than targeting the bacterial cell directly as traditional antibiotics do. This intermediary strategy disrupts the toxin secretion system, providing a novel therapeutic mechanism that bypasses antibiotic resistance mechanisms. This expands therapeutic options while maintaining treatment effectiveness against multidrug-resistant strains.
Data Source
AI summary
Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.